Immunovant (IMVT) Change in Receivables (2021 - 2026)
Immunovant (IMVT) reported Change in Receivables of -$563000.0 for Q1 2026, down 562.35% on a YoY basis from $121768.4 in Q1 2025, and down 76.49% quarter-over-quarter from -$319000.0 in Q4 2025.
Immunovant (IMVT) Change in Receivables (2021 - 2026) Analysis & Trends
Immunovant has reported Change in Receivables for 6 years, with the latest figure at -$563000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables fell 562.35% year-over-year to -$563000.0; the trailing twelve-month figure through Mar 2026 stood at -$986000.0 (up 69.49% YoY), and the FY2026 full-year result was -$986000.0, up 69.49% from the prior year.
- Change in Receivables for Q1 2026 stood at -$563000.0, down from -$319000.0 in the prior quarter.
- The five-year high for Change in Receivables was $4.1 million in Q1 2024, with the low at -$9.8 million in Q3 2022.
- Historically, Change in Receivables has averaged -$452352.9 across 5 years, with a median of -$85000.0 in 2025.
- Annual changes were most pronounced in 2022 — Change in Receivables sank 5616.38% — and 2024, when it jumped 207100.0%.
- Immunovant's Change in Receivables stood at -$2.9 million in 2022, then jumped by 90.97% to -$266000.0 in 2023, then jumped by 174.06% to $197000.0 in 2024, then plunged by 261.93% to -$319000.0 in 2025, then sank by 76.49% to -$563000.0 in 2026.
- The last three Change in Receivables figures came in at -$563000.0 (Q1 2026), -$319000.0 (Q4 2025), and $25000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -4.08 Mn |
| 10 | Immunovant | 5.71 Bn | 5.71 Bn | - | -563,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -563,000.00 |
| Mar 31, 2026 | -563,000.00 |
| Dec 31, 2025 | -319,000.00 |
| Dec 31, 2025 | -319,000.00 |
| Sep 30, 2025 | 25,000.00 |
| Sep 30, 2025 | 25,000.00 |
| Jun 30, 2025 | -129,000.00 |
| Jun 30, 2025 | -129,000.00 |
| Mar 31, 2025 | -85,000.00 |
| Mar 31, 2025 | -85,000.00 |
| Dec 31, 2024 | 197,000.00 |
| Dec 31, 2024 | 197,000.00 |
| Sep 30, 2024 | -417,000.00 |
| Sep 30, 2024 | -417,000.00 |
| Jun 30, 2024 | -2.93 Mn |
| Jun 30, 2024 | -2.93 Mn |
| Mar 31, 2024 | 4.14 Mn |
| Mar 31, 2024 | 4.14 Mn |
| Dec 31, 2023 | -266,000.00 |
| Dec 31, 2023 | -266,000.00 |